Matthew Barcus
Stock Analyst at Chardan Capital
(2.50)
# 2,336
Out of 5,154 analysts
21
Total ratings
25%
Success rate
36.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $6.97 | +43.47% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $14.27 | +89.21% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.53 | +1,220.75% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $26.66 | +20.03% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $2,200 | $4.78 | +45,973.30% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.85 | +215.79% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $21.04 | -61.98% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $6.97
Upside: +43.47%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $14.27
Upside: +89.21%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.53
Upside: +1,220.75%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $26.66
Upside: +20.03%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $2,200
Current: $4.78
Upside: +45,973.30%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.85
Upside: +215.79%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $21.04
Upside: -61.98%